Cable Viewer

Currently released so far... 11218 / 251,287

### Browse latest releases

2010/11 2010/12 2011/01 2011/02 2011/03 2011/04 2011/05
2010/11/28 2010/11/29 2010/11/30
2010/12/01 2010/12/02 2010/12/03 2010/12/04 2010/12/05 2010/12/06 2010/12/07 2010/12/08 2010/12/09 2010/12/10 2010/12/11 2010/12/12 2010/12/13 2010/12/14 2010/12/15 2010/12/16 2010/12/17 2010/12/18 2010/12/19 2010/12/20 2010/12/21 2010/12/22 2010/12/23 2010/12/24 2010/12/25 2010/12/26 2010/12/27 2010/12/28 2010/12/29 2010/12/30
2011/01/01 2011/01/02 2011/01/04 2011/01/05 2011/01/07 2011/01/09 2011/01/10 2011/01/11 2011/01/12 2011/01/13 2011/01/14 2011/01/15 2011/01/16 2011/01/17 2011/01/18 2011/01/19 2011/01/20 2011/01/21 2011/01/22 2011/01/23 2011/01/24 2011/01/25 2011/01/26 2011/01/27 2011/01/28 2011/01/29 2011/01/30 2011/01/31
2011/02/01 2011/02/02 2011/02/03 2011/02/04 2011/02/05 2011/02/06 2011/02/07 2011/02/08 2011/02/09 2011/02/10 2011/02/11 2011/02/12 2011/02/13 2011/02/14 2011/02/15 2011/02/16 2011/02/17 2011/02/18 2011/02/19 2011/02/20 2011/02/21 2011/02/22 2011/02/23 2011/02/24 2011/02/25 2011/02/26 2011/02/27 2011/02/28
2011/03/01 2011/03/02 2011/03/03 2011/03/04 2011/03/05 2011/03/06 2011/03/07 2011/03/08 2011/03/09 2011/03/10 2011/03/11 2011/03/13 2011/03/14 2011/03/15 2011/03/16 2011/03/17 2011/03/18 2011/03/19 2011/03/20 2011/03/21 2011/03/22 2011/03/23 2011/03/24 2011/03/25 2011/03/26 2011/03/27 2011/03/28 2011/03/29 2011/03/30 2011/03/31
2011/04/01 2011/04/02 2011/04/03 2011/04/04 2011/04/05 2011/04/06 2011/04/07 2011/04/08 2011/04/09 2011/04/10 2011/04/11 2011/04/12 2011/04/13 2011/04/14 2011/04/15 2011/04/16 2011/04/17 2011/04/18 2011/04/19 2011/04/20 2011/04/21 2011/04/22 2011/04/23 2011/04/24 2011/04/25 2011/04/26 2011/04/27 2011/04/28 2011/04/29 2011/04/30
2011/05/01

### Browse by creation date

66 72 73 75 79 85 86 87 88 89 90 91 92 93 96 97 00 01 02 03 04 05 06 07 08 09 10
1966/12
1972/02 1972/08
1973/04
1975/03
1979/08
1985/03 1985/06
1986/05
1987/06
1988/01
1989/12
1990/01 1990/07 1990/08 1990/10
1991/05
1992/01 1992/12
1993/10
1996/11
1997/12
2000/05 2000/06 2000/09 2000/11
2001/02 2001/03 2001/06 2001/07 2001/10 2001/11
2002/01 2002/02 2002/03 2002/04 2002/07 2002/11 2002/12
2003/01 2003/02 2003/03 2003/04 2003/05 2003/06 2003/07 2003/08 2003/09 2003/10 2003/11 2003/12
2004/01 2004/02 2004/03 2004/04 2004/05 2004/06 2004/07 2004/08 2004/09 2004/10 2004/11 2004/12
2005/01 2005/02 2005/03 2005/04 2005/05 2005/06 2005/07 2005/08 2005/09 2005/10 2005/11 2005/12
2006/01 2006/02 2006/03 2006/04 2006/05 2006/06 2006/07 2006/08 2006/09 2006/10 2006/11 2006/12
2007/01 2007/02 2007/03 2007/04 2007/05 2007/06 2007/07 2007/08 2007/09 2007/10 2007/11 2007/12
2008/01 2008/02 2008/03 2008/04 2008/05 2008/06 2008/07 2008/08 2008/09 2008/10 2008/11 2008/12
2009/01 2009/02 2009/03 2009/04 2009/05 2009/06 2009/07 2009/08 2009/09 2009/10 2009/11 2009/12
2010/01 2010/02

### Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z
Embassy Athens Embassy Asuncion Embassy Astana Embassy Asmara Embassy Ashgabat Embassy Apia Embassy Ankara Embassy Amman Embassy Algiers Embassy Addis Ababa Embassy Accra Embassy Abuja Embassy Abu Dhabi Embassy Abidjan Consulate Auckland Consulate Amsterdam Consulate Adana American Institute Taiwan, Taipei
Embassy Bujumbura Embassy Buenos Aires Embassy Budapest Embassy Bucharest Embassy Brussels Embassy Bridgetown Embassy Bratislava Embassy Brasilia Embassy Bogota Embassy Bishkek Embassy Bern Embassy Berlin Embassy Belmopan Embassy Belgrade Embassy Beirut Embassy Beijing Embassy Banjul Embassy Bangkok Embassy Bandar Seri Begawan Embassy Bamako Embassy Baku Embassy Baghdad Consulate Barcelona
Embassy Copenhagen Embassy Conakry Embassy Colombo Embassy Chisinau Embassy Caracas Embassy Canberra Embassy Cairo Consulate Curacao Consulate Ciudad Juarez Consulate Chennai Consulate Casablanca Consulate Cape Town Consulate Calgary
Embassy Dushanbe Embassy Dublin Embassy Doha Embassy Djibouti Embassy Dili Embassy Dhaka Embassy Dar Es Salaam Embassy Damascus Embassy Dakar Consulate Dubai
Embassy Freetown
Embassy Guatemala Embassy Gaborone Consulate Guayaquil Consulate Guadalajara
Embassy Helsinki Embassy Harare Embassy Hanoi Consulate Ho Chi Minh City Consulate Hermosillo Consulate Hamilton Consulate Hamburg Consulate Halifax
Iran RPO Dubai Embassy Islamabad Consulate Istanbul
Embassy Jakarta Consulate Jerusalem Consulate Jeddah
Embassy Kyiv Embassy Kuwait Embassy Kuala Lumpur Embassy Kinshasa Embassy Kingston Embassy Kigali Embassy Khartoum Embassy Kathmandu Embassy Kampala Embassy Kabul Consulate Kolkata
Embassy Luxembourg Embassy Luanda Embassy London Embassy Ljubljana Embassy Lisbon Embassy Lima Embassy Lilongwe Embassy La Paz Consulate Lahore Consulate Lagos
Mission USOSCE Mission USNATO Mission UNESCO Embassy Muscat Embassy Moscow Embassy Montevideo Embassy Monrovia Embassy Minsk Embassy Mexico Embassy Mbabane Embassy Maputo Embassy Manila Embassy Manama Embassy Managua Embassy Malabo Embassy Madrid Consulate Munich Consulate Mumbai Consulate Montreal Consulate Monterrey Consulate Milan Consulate Melbourne
Embassy Nicosia Embassy New Delhi Embassy Ndjamena Embassy Nassau Embassy Nairobi Consulate Naples
Embassy Ouagadougou Embassy Ottawa Embassy Oslo
Embassy Pristina Embassy Pretoria Embassy Prague Embassy Port Of Spain Embassy Port Louis Embassy Port Au Prince Embassy Phnom Penh Embassy Paris Embassy Paramaribo Embassy Panama Consulate Peshawar
Embassy Quito Consulate Quebec
REO Basrah Embassy Rome Embassy Riyadh Embassy Riga Embassy Reykjavik Embassy Rangoon Embassy Rabat Consulate Rio De Janeiro Consulate Recife
Secretary of State Embassy Suva Embassy Stockholm Embassy Sofia Embassy Skopje Embassy Singapore Embassy Seoul Embassy Sarajevo Embassy Santo Domingo Embassy Santiago Embassy Sanaa Embassy San Salvador Embassy San Jose Consulate Strasbourg Consulate St Petersburg Consulate Shenyang Consulate Shanghai Consulate Sao Paulo
Embassy Tunis Embassy Tripoli Embassy Tokyo Embassy The Hague Embassy Tel Aviv Embassy Tehran Embassy Tegucigalpa Embassy Tbilisi Embassy Tashkent Embassy Tallinn Consulate Toronto Consulate Tijuana
USUN New York USEU Brussels US Office Almaty US Mission Geneva US Interests Section Havana US Delegation, Secretary UNVIE Embassy Ulaanbaatar
Embassy Vilnius Embassy Vienna Embassy Vatican Embassy Valletta Consulate Vladivostok Consulate Vancouver
Embassy Windhoek Embassy Wellington Embassy Warsaw
Embassy Yerevan Embassy Yaounde
Embassy Zagreb

### Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
AF AM AJ ASEC AS AFIN AMGT AU AE AR ABLD AG AY AORC ASIG AEMR APER AMBASSADOR ASEAN AA AL ASUP ABUD AMED AX APECO AID AUC ASECKFRDCVISKIRFPHUMSMIGEG ADANA AFFAIRS AND AN ADCO ARM ATRN AECL AADP ACOA APEC AGRICULTURE ACS ADPM ASCH AMEX ACAO ANET AODE ARF ACBAQ APCS AMG AQ AMCHAMS AORG AGAO ADM AFSI AFSN AINF AIT ASEX AO ATFN AROC AFGHANISTAN AFU AER ALOW AC AZ AVERY AGMT
BA BRUSSELS BR BL BM BEXP BH BTIO BIDEN BO BT BC BU BY BX BG BK BF BBSR BMGT BTIU BE BD BWC BB BP BILAT
CA CW CH CO CONDOLEEZZA CR CASC CSW CVIS CPAS CMGT CS CI CU CJUS CY CDG CE CG CBW COUNTER CN CKGR COUNTERTERRORISM CODEL CWC CJAN CIA CD CLINTON CT CARSON CONS CB CM CFED CLMT CROS CNARC CIDA CBSA CIC CEUDA CHR CITT CAC CACM CVR CDC CAPC COPUOS CBC CBE COM CDB CAN COE COUNTRY CLEARANCE CACS CF CL CIS CTM CV CICTE
DR DEA DA DOMESTIC DHS DAO DCM DEPT DTRA DPRK DEFENSE DE DJ DISENGAGEMENT DOD DEAX DOE DK DS
ENRG EPET ETRD EFIS ECON EK EAID EUN ES EFIN EWWT ECIN EINV ETTC EAGR EC ELAB ECPS EN EG ELTN EAIR EPA ER EI EU EZ ET EIND EINVECONSENVCSJA ECONOMICS EXTERNAL ELN ELECTIONS EMIN EINN EFINECONCS ETRDEINVECINPGOVCS ENIV ECUN EINT ENGR ENNP EUR EAP EEPET ETRDEINVTINTCS ENVI EFTA ETRO ESENV ECINECONCS ENVR ECONOMY ECONOMIC EUMEM EAIDS ETRA ETRN EUREM EFIM EIAR EXIM ERD EAIG ETRC EXBS EINVEFIN ECIP EINDETRD EUC EREL ECA ENERG ENGY ECONCS EINVETC ECONEFIN ESA ETC ETRDECONWTOCS EUNCH
FI FR FREEDOM FTAA FARC FAO FJ FMLN FBI FOR FTA FOREIGN FINANCE FO FISO FDA FAC FOI FM FINR
GG GT GM GV GH GOI GA GTIP GR GZ GE GCC GY GOV GAERC GANGS GL GLOBAL GERARD GF GAZA GTMO
HO HA HK HUMAN HU HR HILLARY HSTC HUMOR HEBRON HI HURI HYMPSK
IWC IR IZ ICAO IV IRS IC IS IT IZPREL IRAQI IO IN IAEA ID ITPHUM ITPGOV ITALIAN IPR INRB IMO ITALY ICRC INTERPOL IQ ICTY INTELSAT IEFIN IA INR IRC IACI ITRA IL ICJ INTERNAL ISRAELI INMARSAT ITU ILC IBRD IMF ILO IDP ITF IBET IGAD IEA IAHRC ICTR IDA IIP INRA INRO IRAJ IF
JP JA JO JOSEPH JOHNNIE JM JUS JAMES
KSCA KNNP KIPR KOLY KS KPAO KMPI KDEM KZ KG KJUS KRVC KICC KTIA KISL KTIP KCRM KWMN KMDR KVPR KV KHLS KU KTFN KIRF KR KPKO KTDB KIRC KGHG KFRD KCOR KE KSUM KPAL KSEP KSTC KGIC KOMC KFLO KAWC KUNR KNPP KIDE KNEI KBIO KPRP KN KWBG KMCA KCIP KTEX KGIT KNSD KCFE KLIG KFLU KBCT KOMS KBTS KACT KCRS KGCC KDRG KWMM KAWK KHIV KSPR KRAD KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KOCI KSTH KPAI KHSA KTLA KO KFSC KVIR KX KFTFN KHDP KPLS KSAF KMFO KRCM KCSY KSAC KPWR KTRD KID KWNM KMRS KICA KRIM KSEO KPOA KCHG KREC KOM KRGY KCMR KSCI KFIN KVRP KPAONZ KCGC KNAR KMOC KWAC KMIG KSEC KIFR KDEMAF KNUC KPIN KPRV KBTR KERG KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KNUP KTER KDDG KPAK KREL KCOM KNNPMNUC KRFD KHUM KDEV KCFC KWWMN KTBT KWMNCS KJUST
LE LY LU LTTE LI LO LH LG LAB LA LABOR LOG LT
MNUC MARR MASS MCAP MIL MO MOPS MU MX MEPI MR MDC MPOS MEETINGS MD MTCRE MK MUCN MY MASC MRCRE ML MA MEPP MAR MAPP MP MT MAS MTS MLS MI MERCOSUR MC MV MEDIA MILI MEPN MG MW MIK MTCR MARAD MZ MOPPS MAPS MCC MASSMNUC MQADHAFI MTRE
NZ NL NATO NO NAFTA NDP NIPP NP NS NPT NU NI NATIONAL NPG NGO NG NK NA NSSP NRR NSG NSC NPA NORAD NT NW NEW NH NSF NV NR NE NSFO NC NAR NASA NZUS
OTRA OEXC OIIP OVIP OAS OREP OSCE OPRC ODIP OSAC OPIC OPDC OFDP OIE OECD OPCW OVP OPAD OFDA OIC OSCI OMIG OBSP ON OCS OCII OHUM OTR OFFICIALS
PGOV PARM PREL PHUM PTER PINR PK PREF POL PINS PSOE PAK PBTS PHSA PAO PM PF PNAT PE POLITICS PARMS PBIO PSI POLINT POLITICAL PARTIES PL PA PROP PO PGOVLO PORG PGOVE PLN PINF PRELP PAS PPA PRGOV PUNE PG PALESTINIAN POLICY PROG PDEM PREFA PDOV PCI PRAM PTBS PSA POSTS PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PBT PGIV PHUMPGOV PCUL PSEPC PREO PAHO PMIL PNG PP PS PHUH PEPR PINT PU PECON POGOV PINL PKFK PY PFOR PHALANAGE PARTY PMAR PHUMPREL PHUS PRL PGOC PNR PGGV PROV PTERE PGOF PHUMBA PEL POV
QA
RICE RUPREL RU RS RIGHTS RO RW RSP RP REACTION REPORT RCMP RSO RF RFE RM RIGHTSPOLMIL ROBERT REGION
SENV SCUL SNAR SOCI SW SMIG SP SZ SA SY SENVKGHG SU SF SAN SR SO SHUM SYR SAARC SL SI SNARCS SWE SN SARS SPCE SNARIZ SCRS SC SIPDIS SEN SNARN SPCVIS STEINBERG SG SIPRS SH SOFA SANC SK ST SEVN
TPHY TW TC TX TU TI TN TS TT TRGY TO TH TBIO TSPL TIP TP TERRORISM TURKEY TSPA TD TZ TFIN TNGD TINT THPY TBID TF TL TV TAGS TK TR TRSY
UNSC UZ USEU US UN UK UP USTR UNGA UNMIK USUN UNESCO UNHRC UY UNO UG UNDC UAE UNAUS UNDESCO UNHCR UNEP UNCHC UNFICYP UNCHR USNC UNIDROIT UNCSD UNDP UNC UNODC USOAS UNPUOS UNCND USPS UNICEF UV UNCHS UNVIE UE USAID
VZ VT VE VTPREL VM VI VAT VN
WS WTRO WITH WHO WTRQ WBG WI WTO WHA WMD WMO WIPO WHTI WFP WB WWARD WA WEU WZ
XM XV XF XR XA XK XH XL XS XG XW XY XE XT XD XZ XX XTAG XQ XB XU XI XC
YM YI YMCS YE
ZR ZI ZANU ZU ZO ZP ZB ZL ZK ZF ZEALAND ZN ZA ZOELLICK ZJ

### Browse by classification

CONFIDENTIAL CONFIDENTIAL//NOFORN SECRET SECRET//NOFORN UNCLASSIFIED UNCLASSIFIED//FOR OFFICIAL USE ONLY

### Community resources

Follow us on Twitter Check our Reddit Twitter this Digg this page Contact us on IRC

courage is contagious

### Viewing cable 06OTTAWA2021, POTENTIAL FOR IPR PROGRESS: CANADA'S PROPOSED

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:

- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.

To understand the justification used for the classification of each cable, please use this WikiSource article as reference.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06OTTAWA2021.

Reference ID | Created | Released | Classification | Origin
--- | --- | --- | --- | ---
06OTTAWA2021 | 2006-06-29 19:07 | 2011-04-28 00:12 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Ottawa

`

    VZCZCXRO5122
    RR RUEHGA RUEHHA RUEHQU RUEHVC
    DE RUEHOT #2021/01 1801957
    ZNR UUUUU ZZH
    R 291957Z JUN 06
    FM AMEMBASSY OTTAWA
    TO RUEHC/SECSTATE WASHDC 3024
    INFO RUCNCAN/ALL CANADIAN POSTS COLLECTIVE
    RUCPDOC/DEPT OF COMMERCE WASHDC

` `

    UNCLAS SECTION 01 OF 02 OTTAWA 002021

    SIPDIS

    SENSITIVE
    SIPDIS

    STATE PASS TO USTR FOR GARDE, ESPINEL, CHANDLER
    STATE PASS TO USDOC FOR GWORD, JBOGER
    STATE PASS TO USPTO FOR MKEPLINGER

    E.O. 12958: N/A
    TAGS: KIPR ECON TBIO CA
    SUBJECT: POTENTIAL FOR IPR PROGRESS:  CANADA'S PROPOSED
    DATA PROTECTION REGULATIONS

    REF: A. OTTAWA 1701

         ¶B. OTTAWA 1317

    ¶1.  (SBU)  Summary:  The GOC has proposed a two-regulation
    package (significantly different from its 2004 proposal)
    consisting of data protection for the innovative
    pharmaceutical industries and "Patented Medicines (Notice of
    Compliance)" for the generic drug industries, a combination
    designed to force compromise between the two sectors.
    Although the innovative pharmaceutical industry organizations
    PhRMA and Rx&D have minor complaints which they hope to have
    addressed in the final regulations (the comment period ends
    July 17), in general the package seems to be a positive
    development for IPR protection in Canada.  In particular, the
    Data Protection regulation is designed to bring Canada into
    compliance with its international obligations to provide
    protection for proprietary data belonging to patent-holding
    companies, something that the Embassy has been encouraging.
    Assuming the proposed rules are finalized, industry observes
    believe that this will be a step forward for Canada's
    protection of IPR and will directly address one complaint
    from the last two Special 301 Reports on Canada.  End Summary.

    The Regulations
    ---------------

    ¶2.  (U)  (SBU)  The Patented Medicines (Notice of Compliance)
    or PMNOC regulation and, to a lesser extent, the Data
    Protection regulation are complex, and we would welcome
    insights from USG experts.  The data protection regulation
    can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle4-e.html
    The PMNOC regulation can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle6-e.html
    Our initial perusal and conversations with contacts have
    provided the following information.

    ¶3.  (SBU) The draft Data Protection regulation stipulates
    that a secondary manufacturer (usually a generic) cannot file
    a new drug submission on the basis of a direct or indirect
    comparison between the new drug and an innovative drug until
    six years after the first notice of compliance was issued to
    the innovator.  The submission will not be approved until at
    least eight years after the first notice of compliance was
    issued.  This data protection period of eight years compares
    favorably to the U.S. "five plus three" period.  (Comment:
    One observer joked to us that now Canada would have better
    data protection than the United States and that the
    innovative industry may start to use this as leverage to
    argue for better data protection in the United States.  End
    comment.)  Both the Canadian industry group Rx&D and PhRMA in
    the United States are preparing comments to submit to Health
    Canada.  From discussions with industry contacts, we believe
    the industry comments will focus on requests for
    clarification, particularly surrounding the transitional
    language that will determine how drug submissions already in
    the pipeline are treated.  A particular point which seems
    unclear to many observers (and of concern to the
    pharmaceutical industry) is paragraph (5) which states that
    the eight year protection period does not apply "if the
    innovative drug is not being marketed in Canada."  We expect
    that the final regulations will clarify how this will be
    applied.  However, the innovative industry's reaction to the
    data protection regulation is positive, with observers
    stating that this will not only bring Canada into compliance
    with its international obligations but will also make the
    country more competitive internationally.
    Qcountry more competitive internationally.

    ¶4.  (SBU)  The Patented Medicines (Notice of Compliance) or
    PMNOC regulation is the part of the package designed to keep
    the generic companies in the deal.  The PMNOC regulation is
    more complex than the data protection regulation, but in
    general it is intended to limit innovative drug companies'
    ability to "evergreen" drug patents, or renew patents based
    on small changes to a drug.  The PMNOC regulation attempts to
    address the unintended consequences of unclear language in
    previous regulation which required court interpretation;
    these include the "possibility that an innovator company may
    delay generic market entry by listing new and sometimes
    irrelevant patents on the basis of minor product revisions."
    In what seems to be a valuable victory for the innovative
    drug industry, however, the PMNOC's Regulatory Impact
    Assessment Statement states that dosage form patents (patents
    that focus on the form of the drug, not its chemical
    composition) deserve "special protection provided by the
    PM(NOC) regulations," adding that this is "particularly true

    OTTAWA 00002021  002 OF 002

    in the case of biologic drugs where effective administration
    of the medicinal ingredient is often dependent on the
    development of new and innovative delivery mechanisms."  The
    generic industry in Canada has not made any public statement
    on the draft regulations, although they will probably submit
    formal comments.  Our contacts also tell us that the generics
    are trying to arrange for meetings with relevant officials
    and members of parliament before the comment period ends on
    July 17.

    GOC Officials' Perspective
    ---------------------------

    ¶5.  (SBU) Our GOC contacts seem confident that these
    regulations will be finalized, with very few changes, in as
    short a period as is possible under Canada's regulatory
    process.  They describe the regulations as fair and balanced,
    and they suggest that neither the innovative nor the generic
    industry should be surprised by the regulations' content.  In
    general, this is what we are hearing from industry contacts
    as well, although industry contacts hesitate to describe
    themselves as happy with the regulations and insist that
    certain changes need to be made.  Any rhetoric about pushing
    for 10 years of data protection such as in Europe seems to be
    more a bargaining tool than an actual goal.  GOC officials
    are aware that both industries, but particularly the
    innovative industry, are eager for a package to be finalized
    and are willing to accept the compromises inherent in these
    proposed regulations.

    Domestic Political Context
    --------------------------

    ¶6.  (SBU) The current Conservative government has been more
    receptive to U.S. concerns about intellectual property
    rights, and domestically the Conservative party is less
    beholden to the generic industry, which is predominantly
    based in the greater Toronto area, a Liberal stronghold.
    (Comment:  a recent bit of much-hyped campaign scandal
    involved questionable donations to a Toronto-area Liberal
    MP--totalling C$54,000--from Apotex Inc's top two executives,
    their wives and six children.  Apotex is Canada's largest
    generic drug company.  End comment.)  The innovative drug
    companies, on the other hand, are primarily based in Quebec,
    where the Conservatives are very interested in picking up
    additional seats.  In general, this suggests that the
    generics industry, which is thought to be responsible for
    delaying progress on the 2004 proposal of the first version
    of these regulations, will not be able to delay progress on
    the new draft regulations.  The most optimistic timeframe for
    final regulations is probably the end of 2006.  As with our
    other IPR goal of amendments to the copyright act, much will
    hinge on whether another election is called in the meantime.
    An election before finalization of the regulations would at
    the very least delay them regulations and could result in yet
    another redraft.

    Visit Canada's Classified Web Site at
    http://www.state.sgov.gov/p/wha/ottawa

    WILKINS

`